APA (7th ed.) Citation

Haraoui, B., Choquette, D., Sciortino, C., Galos, C., Roy, P., Gruben, D., . . . Khraishi, M. (2026). Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study. Rheumatology & Therapy, 13(3), 843. https://doi.org/10.1007/s40744-026-00854-1

Chicago Style (17th ed.) Citation

Haraoui, Boulos, Denis Choquette, Cristina Sciortino, Corina Galos, Patrice Roy, David Gruben, Julie Vaillancourt, John S. Sampalis, and Majed Khraishi. "Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study." Rheumatology & Therapy 13, no. 3 (2026): 843. https://doi.org/10.1007/s40744-026-00854-1.

MLA (9th ed.) Citation

Haraoui, Boulos, et al. "Effectiveness and Safety of Tofacitinib Up to 36 Months in Canadian Patients with Rheumatoid Arthritis: Final Results from the CANTORAL Study." Rheumatology & Therapy, vol. 13, no. 3, 2026, p. 843, https://doi.org/10.1007/s40744-026-00854-1.